Key Takeaways
- Volume-led growth, margin trough: Revenue grew 15% YoY on ~27% volume growth, but EBITDA margin compressed as the new Pakhajan facility ran at just 10% utilization, dragging the quarter into a net loss.
- The Pakhajan ramp is the entire story: The ₹488 crore facility was commissioned in April 2024 and is now the dominant driver of depreciation, interest, and operating costs. Its ramp from 10% to a targeted 90%+ utilization in FY26 will determine the pace of margin recovery.
- Balance sheet has peaked: Management stated debt has peaked and will not be increased further, targeting a debt-to-EBITDA ratio close to 3x by fiscal year-end, with a longer-term zone of 2x to 2.5x.
- Export value lags volume: Export volumes grew ~27%, but a selling price decline pushed export revenue share down from 63% to 61%, a gap management attributes to momentary pricing pressure and shipping delays.
- What to watch next quarter: Whether Pakhajan utilization reaches the guided 20% in Q2, the pace of customer approvals enabling long-term supply agreements, and any stabilization in selling prices that would lift export value share back toward 65%+.
Pakhajan Facility: The Margin Bridge
- Current drag: The facility was capitalized at ~₹488 crores, adding material depreciation and finance costs while running at only 10% capacity for trials and stabilization, which crushed Q1 profitability.
- Utilization pathway: Management expects ~20% utilization in Q2, 50% for the full fiscal year based on soft order booking, and 70% to 80% by end of Q3 or Q4, with full customer qualification by then.
- Product limitation: Product mix optimization can only happen from the Vapi facility; Pakhajan has a dedicated line and does not change products, so margin recovery depends purely on volume absorption of fixed costs.
- Long-term potential: Current installed capacity is only 10% of what is anticipated for future optimal capacity, with significant land available for leverage.
- Next phase trigger: Management will not work on the next expansion phase until 70% utilization is achieved, which is hoped for by the last quarter of FY25.
Parag Jhaveri: "Pakhajan is only right now what we anticipate of the future or optimal capacity is just only 10% what we have put up today. We have so much of land available in Pakhajan and we need to leverage that first."
Margin & Profitability Walk
- EBITDA margin guidance held: Company-level guidance of 19% to 20% and new-capex EBITDA guidance of 20% to 22% were both reaffirmed, with low utilization in the first two quarters expected to be offset by Q3 and Q4.
- Recovery timeline: Management expects EBITDA margin to stabilize back to previous levels by Q3 to Q4 of this year and grow further, driven by rising utilization absorbing fixed costs.
- Negative PAT drivers: The loss was driven by depreciation and finance costs from the new facility, high operational costs at low utilization, and a ~₹2 crore one-off loss from the Europe subsidiary on old stock sold below transfer price.
- Steady-state costs: The current quarter's interest and depreciation are expected to be the steady state going forward, so the margin bridge is entirely about volume absorption.
- Europe subsidiary: The ~₹2 crore loss from selling-price correction on old stock is not expected to recur from next quarter onwards.
Revenue & Demand Environment
- Volume vs. value: Revenue grew 15% YoY driven by ~27% volume growth, but selling price declines compressed the value realization, particularly in exports where revenue share dipped from 63% to 61%.
- FY25 revenue target: Management guided to ₹900 crores plus for FY25, with FY26 revenue expected between ₹1,200 crores and ₹1,300 crores when both facilities run at 90%+ utilization.
- Market context: The industry is growing at a healthy 3% to 4% year-on-year, and Yasho is capturing a small piece of that market growth rather than taking share from competitors.
- Export recovery: Management is confident of bouncing back to 65% plus in export sales, calling the current low momentary, though shipping container availability delays add uncertainty through Q3.
- Competitive moat: Yasho operates in performance and specialty chemistry within rubber and lubricant spaces, not commodities, which helps hold margins. Better pricing, alternate supply chain demand, and a proven delivery record since 2020 are cited as key customer retention factors.
Parag Jhaveri: "We are not into the commodity, number 1. We are more into the performance and the so-called specialty chemistry within the rubber the space or also into the lubricant space. And a lot of our specialty chemicals are really specialized in that nature. And that is helping us to hold up the margin and allow us to grow."
Customer Approvals & Commercial Pipeline
- Approval timeline: Customer approvals for the Pakhajan facility are expected in the next few months, which is the gating factor for ramping utilization and converting trial orders into long-term supply agreements.
- Long-term contracts: Once trials are completed, customers are expected to enter into long-term supply agreements with Yasho, locking in the volume base for the 90%+ utilization target in FY26.
- USA subsidiary: A wholly owned subsidiary has been established and will be operational in a few months, aimed at reaching more end users with ready stock and expanding profit margins by 3% to 5% on those sales.
- Geographic expansion: Beyond the USA, the company is working to establish presence in South America, the Middle East, and other regions, with a focus on the industrial segment.
Balance Sheet & Capital Allocation
- Debt peak: Current debt levels have peaked and the company does not intend to increase debt further, with no debt repayment planned; instead, cash flow will be reinvested.
- Leverage target: Debt-to-EBITDA is expected to be close to 3x by the end of this financial year, with a longer-term target zone of 2x to 2.5x.
- Working capital tailwind: Falling selling prices and raw material prices are reducing working capital requirements, and positive cash flow generation this year will help manage within the current debt level.
- No equity dilution: When asked about a QIP to improve the margin profile and balance sheet, management answered with a flat "No."
- Future capex: No further capex is planned until 70%+ utilization is achieved from the new facility, expected in the last quarter of FY25 or first quarter of FY26.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pakhajan utilization | 50% for the full year, based on soft order booking | FY25 |
| Pakhajan utilization | 70% to 80%, with full customer qualification | End of Q3 or Q4 FY25 |
| Pakhajan + Vapi utilization | Both facilities at 90%+ | FY26 |
| EBITDA margin | 19% to 20% company-level | FY25 |
| EBITDA margin | Stabilize back to previous level, then grow further | Q3 to Q4 FY25 |
| Revenue | ₹900 crores plus | FY25 |
| Revenue | ₹1,200 crores to ₹1,300 crores | FY26 |
| Debt-to-EBITDA | Close to 3x | End of FY25 |
| Debt-to-EBITDA | 2x to 2.5x target zone | No date (longer-term) |
| Next expansion phase | Decision only after 70% utilization achieved | Last quarter FY25 or Q1 FY26 |
| Export revenue share | Bounce back to 65% plus | No date (called "momentary" low) |
| Shipping container delays | Stabilization expected | End of Q3 to early Q4 FY25, but uncertain due to geopolitics |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue from operations | ₹172.87 cr, +15% YoY |
| Volume growth | ~27% YoY |
| EBITDA margin | 19%–20% target for FY25; Q1 constrained by underutilization of Pakhajan facility |
| Profit before tax margin | Impacted by depreciation and finance costs related to new facility |
| PAT | Negative, due to depreciation and interest costs from new plant commercialization |
| Revenue guidance FY25 | ₹900 cr plus |
| Revenue guidance FY26 | ₹1,200 cr to ₹1,300 cr |
| Export revenue share | 61%, down from 63% |
| Total capacity | 32,500 metric tons per annum |
| Pakhajan facility utilization | ~10% currently; expected 20% in Q2, 45%–50% by year end, 70%–80% by Q3–Q4 |
| Vapi facility utilization | Expected to run at ~90% capacity |
| Debt-to-EBITDA | Expected close to 3x by end of FY25; target zone 2–2.5x |
| Term loan repayment FY26 | ₹45 cr to ₹50 cr |
| Europe subsidiary loss | ~₹2 cr, due to selling price correction in Europe |
| US subsidiary margin expansion target | 3% to 5% on sales |